Minerva Neurosciences | NERV - Current Assets


Minerva Neurosciences reported $83.1M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Adma Biologics USD 511.17M 44.66M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Cipla INR 241.47B 7.71B Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 137.28M 10.74M Mar/2026
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
Takeda JPY 3.09T 25.94B Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025